POSSIBILITIES OF POSITRON-EMISSION TOMOGRAPHY IN DIAGNOSIS OF MALIGNANT BRAIN TUMORS (Literature Review)

В диагностике новообразований на дооперационном и послеоперационном этапах позитронно-эмиссионная томография (ПЭТ) является самым информативным методом лучевой диагностики, основным преимуществом которого является определение не только структуры и локализации опухолей (как в случае МРТ – магнитно-резонансная томография и МСКТ – мультиспиральная компьютерная томография), но также и метаболических процессов в них, что дает возможность диагностировать опухолевый процесс на самых ранних сроках, а также разграничить продолженный рост опухоли от псевдопрогрессии на фоне постлучевых некрозов. В настоящее время существует достаточно широкий спектр радиофармпрепаратов, используемых для ПЭТ, при этом наибольшее клиническое значение находят 18F-ФДГ и 11С-МЕТ (18F-фтордиоксиглюкоза и 11С-метионин). В представленном обзоре описывается место позитронно-эмиссионной томографии в диагностике злокачественных опухолей головного мозга, а также указывается на чувствительность разных радиофармпрепаратов при разной патологии головного мозга, что имеет важное значение при все более широком внедрении данного метода диагностики в клиническую практику.In the diagnosis of neoplasms at the preoperative and postoperative stages, positron emission tomography (PET) is the most informative method of radiation diagnosis, the main advantage of which is the determination of not only the structure and localization of tumors (as in the case of MRI and MSCT), but also the metabolic processes in them, which makes it possible to diagnose the tumor process at the earliest possible time, and also to delimit the continued growth of the tumor from pseudo-progression against the background of post-radiation necrosis. Nowadays, there is a fairly wide range of radiopharmaceuticals used for PET, with 18F-FDG and 11C-MET (18F-fluorodeoxyglucose and 11C-methionine) being the most clinically important. This review describes the location of positron emission tomography in the diagnosis of malignant brain tumors, and also points out the sensitivity of various radiopharmaceuticals with different brain pathologies, which is important with the ever wider introduction of this diagnostic method into clinical practice

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. Results: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial [CHEST-2]). Conclusion: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

International audienc

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

International audienc